Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights

Arcadia Biosciences (Nasdaq: RKDA) reported first quarter 2026 results.

Rhea-AI Summary

Arcadia Biosciences (Nasdaq: RKDA) reported first quarter 2026 results. Zola coconut water unit volumes rose 18% year-over-year, supported by a price increase, though total revenues declined 8% to $1.1 million.

Total operating expenses climbed to $1.9 million, while SG&A reached the lowest level in company history. Net loss attributable to common stockholders was $4.4 million, versus $2.6 million net income a year earlier, impacted by a $2.9 million warrant inducement loss. Arcadia also received approximately $2.1 million in gross proceeds from exercises of preferred investment options.

Positive

• Zola coconut water unit volumes up 18% year-over-year
• Total revenues of $1.1 million in Q1 2026
• SG&A expenses at lowest level in company’s public history
• SG&A decreased by $559,000 year-over-year in Q1 2026
• Gross proceeds of approximately $2.1 million from option exercises

Negative

• Total revenues decreased by $100,000 (8%) year-over-year
• Total operating expenses increased by $1.2 million year-over-year
• Net result swung to $4.4 million loss from $2.6 million income
• Q1 2026 warrant inducement offer generated a $2.9 million loss
• Additional other loss of $1.5 million in Q1 2026
• Loss from continuing operations of $779,000 versus $530,000 income

Argus May 15 session

-10.69% close to close Open Argus

Details

News Market Reaction – RKDA

In the May 15 session, RKDA declined 10.69%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -10.7% in the session following this news. A negative reaction despite Zola’s 18% ...

Analysis

The stock dropped -10.7% in the session following this news. A negative reaction despite Zola’s 18% volume growth fits past earnings patterns, where updates have averaged a -0.94% move amid mixed fundamentals. Q1 2026 showed revenue down to $1.1M, operating expenses up to $1.879M, and a $4.4M net loss influenced by a $2.9M warrant inducement loss. Continued going-concern language and an S‑3 registration for up to 1,673,792 shares, with potential dilution, add to downside risk assessments.

Key Figures

Total revenue: $1.1M Operating expenses: $1.879M Net (loss) income to stockholders: $4.4M loss +5 more

Total revenue

$1.1M

Q1 2026, vs $1.2M in Q1 2025 (down 8%)

Operating expenses

$1.879M

Q1 2026, vs $0.670M in Q1 2025

Net (loss) income to stockholders

$4.4M loss

Q1 2026, vs $2.6M income in Q1 2025

EPS

($2.11) vs $1.90

Q1 2026 vs Q1 2025 net income per share

Zola volume growth

18%

Zola coconut water unit volumes YoY in Q1 2026

Gross proceeds

$2.1M

Exercise of previously outstanding preferred investment options

SG&A change

$559K decrease

Q1 2026 vs Q1 2025 SG&A expenses

Warrant inducement loss

$2.9M

Loss related to January 2026 warrant inducement offer

Previous Earnings Reports

5 past events · Latest: Mar 26

Same Type 5 events

1. Mar 26

   Q4/FY 2025 earnings

   24h Move

   -3.3%

   Reported Q4/FY25 results, Zola growth, and Roosevelt deal termination.

2. Nov 07

   Q3 2025 earnings

   24h Move

   -2.2%

   Mixed Q3 with Zola growth, strong margins, and large credit loss.

3. Aug 14

   Q2 2025 earnings

   24h Move

   +5.6%

   Q2 revenue growth offset by major credit loss and net loss swing.

4. May 08

   Q1 2025 earnings

   24h Move

   -0.2%

   Strong Q1 2025, revenue up 22% and return to net income.

5. Mar 20

   Q4/FY 2024 earnings

   24h Move

   -4.5%

   Strong 2024 Zola growth and asset sales but continued net loss.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

revenue reserve, contingent consideration liability, warrant inducement offer transaction, Form 8-K, +1 more

5 terms

revenue reserve financial

"driven primarily by a revenue reserve release of approximately $193,000 in 2025."

A revenue reserve is a portion of a company’s profit that management keeps on the balance sheet instead of paying out to owners, like putting some earnings into a savings jar for future needs. It matters to investors because it strengthens the company’s ability to weather downturns, fund growth, or support dividends later; larger or growing reserves can signal financial prudence, while shrinking reserves may warn of cash strain or heavy payouts.

contingent consideration liability financial

"and $1.0 million gain related to the change in fair value of contingent consideration liability in the first quarter of 2025."

Contingent consideration liability is an obligation a company records when it may owe future payments tied to the outcome of a past deal, such as extra cash or shares if certain targets are met. Think of it like a promised bonus that depends on future results; it matters to investors because it can change a company's reported debt, future cash needs, and reported earnings volatility as those contingent payments are re-estimated over time.

warrant inducement offer transaction financial

"driven by the loss relating to the company’s January 2026 warrant inducement offer transaction of $2.9 million"

A warrant inducement offer transaction is when a company grants warrants—options to buy its stock at a fixed price in the future—to certain stakeholders as a sweetener to secure their approval, cooperation, or settlement for a corporate action. Think of it like offering coupons to neighbors to win support for a shared project: it can help get a deal done but also creates the possibility of more shares being issued later, which can dilute existing ownership and affect the stock’s future value, so investors need to weigh the trade-off between short-term progress and long-term share dilution.

Form 8-K regulatory

"included in the company’s Report on Form 8-K and Quarterly Report on Form 10-Q"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

Form 10-Q regulatory

"included in the company’s Report on Form 8-K and Quarterly Report on Form 10-Q"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

 -- Zola^® volumes increase 18% year-over-year --

-- SG&A at lowest level in Arcadia’s history --

DALLAS, May 14, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the first quarter of 2026.

“We are very pleased with our performance during the first quarter of 2026,” said T.J. Schaefer, CEO of Arcadia. “We were able to bring in gross proceeds of approximately $2.1 million from the exercise of previously outstanding preferred investment options, Zola^® coconut water revenues and volumes increased at a double-digit rate compared to the same quarter last year, and our selling, general, and administrative expenses are at the lowest level in Arcadia’s history as a public company.

“Going forward, we continue to evaluate strategic alternatives but also remain focused on growing our Zola coconut water brand and are excited about the prospects of launching a new product that we expect to be on the shelves of many of our largest customers this fall,” Schaefer added.

Arcadia Biosciences, Inc. Financial Snapshot (Unaudited) ($ in thousands)
	Three Months Ended March 31,
	2026		2025		Favorable / (Unfavorable)
					$		%
Total revenues	1,100		1,200		(100)		(8%)
Total operating expenses	1,879		670		(1,209)		(180%)
(Loss) income from continuing operations	(779)		530		(1,309)		(247%)
Net (loss) income attributable to common stockholders	(4,385)		2,599		(6,984)		(269%)

More detailed financial information is included in the company’s Report on Form 8-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), available in the Investors section of the company’s website under SEC Filings.

Revenues
Sales of Zola coconut water unit volumes increased 18% and also benefitted from a price increase that went into effect at the beginning of the year. However, reported revenues decreased $100,000, or 8%, during the first quarter of 2026 compared to the same period in 2025, driven primarily by a revenue reserve release of approximately $193,000 in 2025.

Operating Expenses
Total operating expenses increased by $1.2 million during the first quarter of 2026 compared to the same period in 2025 due to the $750,000 gain on sale of the company’s reduced gluten and oxidative stability patent portfolios and $1.0 million gain related to the change in fair value of contingent consideration liability in the first quarter of 2025.

Cost of revenues increased $18,000, or 3%, during the first quarter of 2026 compared to the same period in 2025 driven primarily by the increase in Zola sales volume, which increased product costs and freight expenses.

Selling, general, and administrative expenses decreased by $559,000 during the first quarter of 2026 compared to the same period in 2025, driven primarily by the absence of M&A fees and lower employee costs in the first quarter of 2026.

Net Loss (Income) Attributable to Common Stockholders
Net loss attributable to common stockholders for the first quarter of 2026 was $4.4 million, or $2.11 per share, a $7.0 million decrease from the $2.6 million net income, or $1.90 per share, for the first quarter of 2025. The decrease was primarily driven by the loss relating to the company’s January 2026 warrant inducement offer transaction of $2.9 million and other loss of $1.5 million, in addition to the $750,000 gain on sale of the company’s reduced gluten and oxidative stability patent portfolios and $1.0 million gain related to the change in fair value of contingent consideration liability in the first quarter of 2025.

About Arcadia Biosciences, Inc.
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products. For more information, visit www.arcadiabio.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future results of operations concerning the company and its products, including, but not limited to, statements relating to Zola products and sales, the company’s growth, cash position, operating costs, financial performance, evaluation of possible strategic alternatives and transactions, and the impact on shareholder value. Undue reliance should not be placed on any forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from the results anticipated by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks set forth in filings that the company makes with the Securities and Exchange Commission from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2025 (the 2025 Form 10-K), and other filings that the company makes with the SEC. Forward-looking statements concerning anticipated future activities also assume that the company has sufficient funding to continue its operations and planned activities, which may not be the case. As described in greater detail in the 2025 Form 10-K and in the company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026, the company will require additional funding in the near future to continue its operations and planned activities. There are no assurances that required funding will be available at all or will be available in sufficient amounts or on reasonable terms. The company may seek to raise additional funds through equity or debt financings, through transactions involving its other assets, or through other transactions. Any sale of additional equity securities could result in dilution to company stockholders. Reported results should not be considered as an indication of future performance. Forward-looking statements made in this press release speak only as of the date hereof, and except as required by law, Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements or to reflect events or circumstances arising after the date of this press release.

Arcadia Biosciences Contact:
T.J. Schaefer
ir@arcadiabio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Arcadia Biosciences (RKDA) Q1 2026 financial results?

Arcadia Biosciences reported Q1 2026 revenues of $1.1 million and a net loss attributable to common stockholders of $4.4 million. According to Arcadia, this compares with $1.2 million in revenues and $2.6 million net income in Q1 2025, reflecting higher expenses and transaction-related losses.

Why did Arcadia Biosciences (RKDA) revenue fall 8% in Q1 2026 despite Zola growth?

Revenue decreased 8% year-over-year to $1.1 million, even though Zola unit volumes rose 18%. According to Arcadia, the decline was mainly due to a prior-year revenue reserve release of about $193,000 that benefited Q1 2025 but did not recur in 2026.

How did Zola coconut water perform for Arcadia Biosciences (RKDA) in Q1 2026?

Zola coconut water unit volumes grew 18% year-over-year in Q1 2026 and also benefited from a price increase. According to Arcadia, this volume and pricing improvement drove higher product costs and freight, contributing to a 3% rise in cost of revenues versus Q1 2025.

What caused Arcadia Biosciences (RKDA) to report a $4.4 million net loss in Q1 2026?

The Q1 2026 net loss of $4.4 million was driven by several non-operating items. According to Arcadia, key factors included a $2.9 million loss from a January 2026 warrant inducement offer and $1.5 million of other loss, plus non-repeated gains recorded in Q1 2025.

How did operating expenses and SG&A trend for Arcadia Biosciences (RKDA) in Q1 2026?

Total operating expenses rose to $1.9 million in Q1 2026, up about $1.2 million year-over-year. According to Arcadia, the increase reflected absence of prior gains, while SG&A fell $559,000 and reached the lowest level in the company’s history as a public company.

How much capital did Arcadia Biosciences (RKDA) raise from option exercises in early 2026?

Arcadia Biosciences received approximately $2.1 million in gross proceeds from exercises of previously outstanding preferred investment options. According to Arcadia, this capital was realized during the first quarter of 2026 and supports ongoing operations alongside efforts to grow the Zola coconut water brand.

What strategic plans and product launches did Arcadia Biosciences (RKDA) discuss with Q1 2026 results?

Arcadia indicated it continues to evaluate strategic alternatives while focusing on expanding the Zola brand. According to Arcadia, the company is also preparing a new product it expects to place with many of its largest customers in the fall, subject to execution and market conditions.